search icon
      blog search icon

      Sonoma Pharmaceuticals Inc. (SNOA) stock rises during pre-market trading. Here’s to know why? - Stocks Telegraph

      By ST Staff

      Published on

      April 1, 2021

      9:54 AM UTC

      Last Updated on

      August 2, 2021

      5:11 AM UTC

      Sonoma Pharmaceuticals Inc. (SNOA) stock rises during pre-market trading. Here’s to know why? - Stocks Telegraph

      Sonoma Pharmaceuticals Inc. (SNOA) stock surged by 8.47% at the last trading close whereas the SNOA rises by 26.78% in the pre-market trading after it announced their agreement with EMC Pharma, LLC. Sonoma Pharmaceuticals is a worldwide healthcare pioneer in the development and production of stabilized hypochlorous acid (HOCl) products for wound treatment, animal health, eye care, nasal care, oral care, disinfectant use, and dermatological conditions.

      What is happening?

      Sonoma announced that it has entered into a definitive agreement with EMC Pharma, LLC for the exclusive right to manage, market, and distribute Sonoma’s HOCl-based prescription dermatology and eye care products in the United States for a five-year period, with an option to extend. EMC Pharma will also have a non-exclusive contract with the government to manage, supply, and distribute such Microcyn-based wound care products. EMC Pharma is a national healthcare products and services firm that operates in FDA-approved prescription medication creation, pharmaceutical distribution, and effective pharmacy services.

      EMC will purchase all of the current inventory and pay a royalty and transfer rates for the first five years as part of the collaboration deal. To keep the distribution rights reserved, the parties agreed on certain minimum purchase conditions. The CEO of SNOA said that, through this agreement with EMC we are intending to increase our distributor network in order to enhance their approach for patients and consumers on national level and for this purpose EMC is the most appropriate platform due to its wide distribution network and experience in this business.


      Sonoma’s direct sale model was not really working in favor of SNOA therefore following this new agreement SNOA has reduced its sales force, working for the direct sale model in USA. The management of SNOA hopes that partnering with EMC would enable the company to cut costs while working with EMC to develop a profitable distribution model for its prescription drugs.

      Hence, this recent development in SNOA has caught the attention of investors which resulted in the rise of SNOA stock price. But the investors are still expected to be more careful before they make bet for a long-term.

      More From Stocks telegraph